


SHITARA, K. et al.  
Serial No. unknown  
national phase of PCT/JP00/03957

**REMARKS**

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:   
B. J. Sadoff  
Reg. No. 36,663

BJS:ecb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

Page 1, before the first line, insert as a separate paragraph:

--This application is the U.S. national phase of international application  
PCT/JP00/03957 filed 16 June 2000, which designated the U.S.--

Page 80, line 19, after "anti-CD34 antibody", please insert

--with monocytes and lymphocytes--

**IN THE CLAIMS**

10. (Amended) The reagent according to any ~~one of~~ claims 2 ~~to~~ 9, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

20. (Amended) The method according to any ~~one of~~ claims 12 ~~to~~ 19, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

31. (Amended) The diagnostic agent according to any ~~one of~~ claims 23 ~~to~~ 30, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

42. (Amended) The diagnostic method according to ~~any one of claims 34 to 41~~, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

53. (Amended) The inhibitor of migration of a monocyte and/or a macrophage according to ~~any one of claims 45 to 52~~, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

65. (Amended) The therapeutic agent according to ~~any one of claims 57 to 64~~, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.